The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Last week was an event-filled one for the biotech space, with M&A, FDA decisions, clinical trial results and earnings all on offer.

Biogen Inc (NASDAQ: $BIIB) announced an $800-million deal to buy Nightstar Therapeutics PLC (NASDAQ: $NITE).

Bio-Path Holdings Inc (NASDAQ: $BPTH) was the biotech performer of the week, advancing more than 250 percent.

Depression drugs had contrasting effects on Johnson & Johnson (NYSE: $JNJ) and Allergan plc (NYSE: $AGN), with the former’s novel treatment-resistant depression drug passing FDA muster — although with a boxed warning — while the latter’s major depressive disorder drug flunked a late-stage trial.

Related Link: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

The following are key biotech catalysts that could sway stocks in the unfolding week.


  • 13th Annual Conference on Stem Cell & Regenerative Medicine – March 11-12 in Nice, France
  • Cowen & Co. 39th Healthcare Conference – March 11-13 in Boston, Massachusetts
  • 13th Annual Canaccord Genuity Musculoskeletal Conference – March 12 in Las Vegas
  • Barclays Global Healthcare Conference 2019 – March 12-14 in Miami Beach
  • 20th World Dermatology Congress – March 13-14 in Singapore City, Singapore
  • 12th World Congress on Virology and Infectious Diseases – March 13-14 in Singapore City
  • BioCapital Europe 2019, organized by Life Sciences Partners – March 14 in Amsterdam, The Netherlands
  • Annual Congress on Neurology & Neuroscience – March 14-15 in Paris, France
  • European Autism Congress – March 14-15 in Zagreb, Croatia
  • 4th Global Summit on Heart Diseases – March 15-16 in Singapore City


The FDA is set to rule on Regeneron Pharmaceuticals Inc (NASDAQ: $REGN) and Sanofi SA (NASDAQ: $SNY)’s sBLA for Dupixent, with the approval being sought for an expanded indication to include adolescents with moderate-to-severe atopic dermatitis. The PDUFA date is scheduled for Monday.

Roche Holdings AG Basel ADR (OTC: $RHHBY) and Celgene Corporation (NASDAQ: $CELG) await a FDA nod for Tecentriq plus chemotherapy Abraxane as first-line treatment of unresectable, locally advanced or metastatic triple-negative breast cancer in people whose disease expresses PD-L1 protein, as determined by PD-L1 biomarker testing. The PDUFA date is set for Tuesday.

The FDA will decide on Aerie Pharmaceuticals Inc (NASDAQ: $AERI)’s NDA for Roclatan — its investigational once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The PDUFA date is scheduled for Thursday.

See Also: What’s Behind TrovaGene’s Volatile Ride?



  • Athenex Inc (NASDAQ: $ATNX) (before the market open)
  • Dicerna Pharmaceuticals Inc (NASDAQ: $DRNA) (after the market close)
  • Oxford Immunotec Global PLC (NASDAQ: $OXFD) (after the market close)
  • Kala Pharmaceuticals Inc (NASDAQ: $KALA) (after the market close)
  • Zafgen Inc (NASDAQ: $ZFGN) (after the market close)


  • Corbus Pharmaceuticals Holdings Inc (NASDAQ: $CRBP) (before the market open)
  • Aratana Therapeutics Inc (NASDAQ: $PETX) (after the market close)
  • Clearside Biomedical Inc (NASDAQ: $CLSD) (after the market close)
  • Verastem Inc (NASDAQ: $VSTM) (after the market close)
  • Inovio Pharmaceuticals Inc (NASDAQ: $INO) (after the market close)


  • Trevena Inc (NASDAQ: $TRVN) (before the market open)
  • Galmed Pharmaceuticals Ltd (NASDAQ: $GLMD) (before the market open)
  • Infinity Pharmaceuticals Inc. (NASDAQ: $INFI) (before the market open)
  • Miragen Therapeutics Inc (NASDAQ: $MGEN) (after the market close)
  • Melinta Therapeutics Inc (NASDAQ: $MLNT) (after the market close)


  • Neos Therapeutics Inc (NASDAQ: $NEOS) (before the market open)
  • Catabasis Pharmaceuticals Inc (NASDAQ: $CATB) (before the market open)
  • Tetraphase Pharmaceuticals Inc (NASDAQ: $TTPH) (after the market close)
  • Zosano Pharma Corp (NASDAQ: $ZSAN) (after the market close)
  • BioDelivery Sciences International, Inc. (NASDAQ: $BDSI) (after the market close)


  • Diplomat Pharmacy Inc (NYSE: $DPLO) (after the market close)

IPO Quiet Period Expiry

  • Avedro Inc (NASDAQ: $AVDR)
  • Tcr2 Therapeutics Inc (NASDAQ: $TCRR)
  • Hoth Therapeutics Inc (NASDAQ: $HOTH)
  • Stealth BioTherapeutics Corp (NASDAQ: $MITO)
  • Soliton Inc (NASDAQ: $SOLY)

© 2019 Benzinga does not provide investment advice. All rights reserved.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Done Reading? You might also find these links useful:
Stock Market News | Stocks Catalyst Calendar | Social Activity Stream | Stock Forums | Stocks Chat Rooms